N
SIOX

Natixis’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Natixis’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-16,000
Closed -$44K – 1215
2020
Q4 		$44K Buy
+16,000
New +$46.6K ﹤0.01% 1027

Other funds holding SIOX

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TVWM
Tower View Wealth Management Shorewood, Wisconsin $227M AUM 41.04% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Natixis's SIOX Position: Q1 2021 in Review

Natixis sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2021, closing a stake of 16,000 shares — an estimated $44K sold.

Natixis first reported a position in SIOX in Q4 2020 and held it in 1 quarter. The position peaked at $44K in Q4 2020. 56 funds tracked by Wall St. Rank hold SIOX as of Q1 2021.

  • Natixis reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Natixis sold 16,000 Sio Gene Therapies Inc. Common Stock shares in Q1 2021, an estimated $44K.
  • Natixis first reported a position in Sio Gene Therapies Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Natixis's Sio Gene Therapies Inc. Common Stock position peaked at $44K in Q4 2020.
  • 56 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2021.

Based on Natixis's 13F filing for Q1 2021, filed 14 May 2021.